Virobay
2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more
2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more
2010 – Virobay closes Series B financing
2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple development candidates are poised for Phase I
2007 – In-licensed cathepsin protease inhibitor assets
2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C
2006 – Founded as a protease inhibitor drug discovery and development company
News
December 5, 2012
Cathepsin S, Virobays lead drug candidate, was selected by Windhover as one of the top 10 most interesting inflammatory/autoimmune projects available for partnering.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive anti-inflammatory/autoimmune opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence.
"Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."
Link to presentation "Cathepsin S Inhibitors for the Treatment of Inflammatory Bowel Disease"
Press Releases
January 9, 2012
LEO Pharma A/S in-licenses promising compound from Virobay Inc. for oral treatment of psoriasis
November 14, 2011
Virobay's spectrum-selective cathepsin inhibitor shows efficacy in bone cancer model
November 3, 2011